- Corporate
Basilea Pharmaceutica Ltd. is
headquartered in Basel, Switzerland, and listed on the SIX
Swiss Exchange (SIX:BSLN). Its fully integrated research and development
operations are currently focused on antibiotics and antifungals, as well as on
the development of dermatology and oncology drugs, targeting the medical
challenge of resistance and non-response to current treatment options in the
hospital and specialty care setting.
News
Basel, Switzerland, April 17, 2012 - Basilea Pharmaceutica Ltd. (SIX:BSLN) shareholders approve all Board of Directors' proposals at this year's Ordinary General Meeting.
more...
Basel, Switzerland, April 4, 2012 - Research data on a potential biomarker predicting response to Basilea's novel microtubule-targeting phase I oncology drug candidate BAL101553 were presented at the American Association of Cancer Research (AACR) Annual Meeting in Chicago, Illinois, USA.
more...
Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today topline results from its U.S. phase III HANDEL study with its investigational compound oral alitretinoin in severe chronic hand eczema (CHE) refractory to potent topical corticosteroids. The results cover observations made during the treatment period and the first six-month post-treatment observation period.
more...
Basilea Pharmaceutica Ltd. (SIX:BSLN) today presented solid financial results for the full-year 2011 with a year-end cash position of CHF 197.1 million and a lower than expected operating loss of CHF 57.3 million. In 2011, sales of Basilea's hand eczema drug Toctino® (alitretinoin) increased to CHF 31.0 million in line with the company's guidance, representing a year-on-year volume growth of 24 percent.
more...
© 2012 Basilea Pharmaceutica Ltd.
